Article
Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells.
Nature communications - 26 Sept 2022
Wang Qiwei, Liu Ying, Wang Hui, Jiang Penglei, Qian Wenchang, You Min, Han Yingli, Zeng Xin, Li Jinxin, Lu Huan, Jiang Lingli, Zhu Meng, Li Shilin, Huang Kang, Tang Mingmin, Wang Xinlian, Yan Liang, Xiong Zecheng, Shi Xinghua, Bai Ge, Liu Huibiao, Li Yuliang, Zhao Yuliang, Chen Chunying, Qian Pengxu
Abstract excerpt
DNA methyltransferase 3 A (DNMT3A) is the most frequently mutated gene in acute myeloid leukemia (AML). Although chemotherapy agents have improved outcomes for DNMT3A-mutant AML patients, there is still no targeted therapy highlighting the need for further study of how DNMT3A mutations affect AML phenotype. Here, we demonstrate that cell adhesion-related genes are predominantly enriched in DNMT3A-mutant AML cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.